CIR
LIVE

Serial Number

98088355

Owner

NKILT Therapeutics, Inc.

Attorney

Bret E. Field

Filing Date

Jul 17, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CIR Trademark

Serial Number: 98088355

CIR is a trademark filed by NKILT Therapeutics, Inc. on July 17, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

NKILT Therapeutics, Inc.

266 Northview Terrace
Springfield, NJ 07081

Entity Type: 03

Trademark Details

Filing Date

July 17, 2023

Registration Date

Not Registered

Published for Opposition

April 30, 2024

Goods & Services

Medical services, in particular in the field of immunotherapy, in particular in the field of immuno-oncology; medical services in the field of hyperproliferative diseases; medical services in the field of cancer; medical services in the field of anti-infectives; in particular all of the aforesaid services related to the use of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages

Scientific and technological services, namely, scientific research, analysis and testing in the field of biology, pharmaceuticals and cell therapy; biological research and development; medical, pharmaceutical and biotechnological research

Chemical and biochemical preparations for scientific purposes, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for laboratory and experimentation purposes, in particular for conducting experimental assays, other than for medical or veterinary purposes; reagents for scientific and research use, namely, reagents such as proteins and nucleic acids for modifying cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages

Pharmaceutical preparations, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; living cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; biological preparations in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; therapeutic pharmaceuticals utilizing cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages in the treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; cell preparations such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 29, 2025 EXRA
SOU EXTENSION 3 GRANTED
Dec 29, 2025 EX3G
SOU EXTENSION 3 FILED
Dec 23, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 23, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 3, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jul 2, 2025 EX2G
SOU EXTENSION 2 FILED
Jun 25, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 25, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 2, 2025 EXRA
SOU EXTENSION 1 GRANTED
Apr 2, 2025 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 31, 2025 AITU
SOU EXTENSION 1 FILED
Dec 16, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 16, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 25, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 30, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 10, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 25, 2024 CNSA
ASSIGNED TO EXAMINER
Mar 22, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 15, 2023 NWOS
NEW APPLICATION ENTERED
Jul 20, 2023 NWAP